BridgeBio Pharma (BBIO) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and BridgeBio published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Q3 2026 license and services revenue includes a one-time $75.0 million sales milestone from Bayer for Beyonttra, the name acoramidis is sold under in Europe.
• EPS is net loss attributable to common stockholders, which in Q3 2026 includes $26.3 million of dividends and accretion on Series A preferred stock BridgeBio issued during the quarter. Net loss attributable to BridgeBio was $56.7 million.

Source: BridgeBio Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How BridgeBio splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• BridgeBio's Net product revenue revenue was $253 million in Q3 2026, up 134% from $108 million in Q3 2025, 72% of total revenue.
• BridgeBio's License and services revenue revenue was $79.3 million in Q3 2026, up 854% from $8.3 million in Q3 2025, 22% of total revenue.
• BridgeBio's Royalty revenue revenue was $20.5 million in Q3 2026, up 379% from $4.3 million in Q3 2025, 6% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues, net and net loss per share (basic and diluted), each as first reported in that quarter's release.

We do not hold a confirmed date for BridgeBio's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

BridgeBio had total revenues of $353.2 million in Q3 2026, against $120.7 million a year earlier. U.S. Attruby net product revenue was $253.2 million, up approximately $31 million from Q2 2026 and $145 million from a year earlier. Rest of World Attruby revenue was $0.1 million, royalty revenue $20.5 million and license and services revenue $79.3 million. (BridgeBio Q3 2026 release, Oct 29, 2026)

Attruby (acoramidis) treats transthyretin amyloid cardiomyopathy (ATTR-CM). BridgeBio said growth was again led by the treatment-naive segment, with more newly diagnosed patients starting treatment and a rising Attruby share of those starts. In the U.S. it is distributed through a limited network of specialty pharmacies, specialty distributors and third-party logistics providers. (BridgeBio Q3 2026 release, Oct 29, 2026; BridgeBio Form 10-K, 2025, Feb 24, 2026)

License and services revenue jumped because of a one-time $75.0 million sales milestone under BridgeBio's license agreement with Bayer, which sells acoramidis in Europe as Beyonttra; Alexion commercializes it in Japan. Royalty revenue rose on Beyonttra sales in the EU, approved in February 2025, and in Japan, after pricing approval in May 2025. (BridgeBio Form 10-Q, Q3 2026, Oct 29, 2026; BridgeBio Form 10-K, 2025, Feb 24, 2026)

Revenue is concentrated. Bayer accounted for 19.4% of consolidated gross revenues in Q3 2026, and five other customers each accounted for between 12.2% and 19.1%. (BridgeBio Form 10-Q, Q3 2026, Oct 29, 2026)

BridgeBio reported a net loss attributable to common stockholders of $83.0 million, or $0.42 per share, in Q3 2026, against $182.7 million, or $0.95, a year earlier. It does not report an adjusted EPS figure. The loss from operations narrowed to $11.6 million from $145.2 million, which BridgeBio attributed to higher revenue and the $75.0 million Bayer milestone. (BridgeBio Q3 2026 release, Oct 29, 2026)

Below operating income, BridgeBio recorded $42.3 million of noncash interest expense on deferred royalty obligations and $13.3 million of interest expense. The per-share loss also absorbs $26.3 million of dividends and accretion on Series A preferred stock issued in the quarter for net proceeds of $932.6 million. Operating costs rose to $364.8 million, including a $63.2 million increase in SG&A and a $30.6 million increase in R&D. (BridgeBio Q3 2026 release, Oct 29, 2026; BridgeBio Form 10-Q, Q3 2026, Oct 29, 2026)

Weighted-average shares were 196,029,851, against 191,854,152 a year earlier. BridgeBio repurchased 712,165 shares for $47.5 million in the quarter under a $500.0 million program approved in May 2026. (BridgeBio Q3 2026 release, Oct 29, 2026; BridgeBio Form 10-Q, Q3 2026, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

BridgeBio does not publish a revenue or earnings outlook in its release. What it does set out is a calendar of regulatory decisions: a November 27, 2026 PDUFA date for BBP-418 in LGMD2I/R9, February 4, 2027 for oral infigratinib in achondroplasia and May 8, 2027 for encaleret in ADH1, each with Priority Review. (BridgeBio Q3 2026 release, Oct 29, 2026)

BridgeBio said cash, cash equivalents and marketable securities of $1.5 billion at September 30, 2026 fully fund all three launches and expansion indications. (BridgeBio Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover BridgeBio, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones BridgeBio's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning BBIO is on is BBIO a buy or a sell?, what analysts expect next is on the BBIO forecast, and what the company does is on the BridgeBio Pharma (BBIO) stock page.

Every number on this page can be traced to a document BridgeBio published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.